Cancer Biostatistics Scientific Impact
Here is a summary of some recent major scientific discoveries facilitated the Cancer Biostatistics (CB) Shared Resource.
Scientific Finding:
Sulindac plus erlotinib reduces duodenal polyps in FAP patients
Services Used:
- Clinical trial design in P01 application
- Interim and final analysis
- Manuscript preparation and revision
Citation:
- JAMA 2016, 315 (12): 1266
- JAMA Oncol 2018 (Epub)
Scientific Finding:
Telecare increased colonoscopy uptake regardless of cost barriers
Services Used:
- Trial design in R01 application
- Analysis
- Manuscript preparation
Citation:
- Cancer Epidemiol Biomarkers Prev 2015, 24(9): 1311
Scientific Finding:
Association between socioeconomic factors and breast cancer survival differs by race
Services Used:
- Statistical analysis
- Manuscript preparation
Citation:
- PLoS One 2017, 12(12) e0187018
Scientific Finding:
Breast conservation surgery associated with superior cancer-specific survival to mastectomy or mastectomy plus radiation
Services Used:
- Statistical analysis
- Manuscript preparation
Citation:
- JAMA Surgery 2014,149 (3): 267
Scientific Finding:
Response to 7 days of tamoxifen is similar to longer courses in breast cancer patients
Services Used:
- Clinical trial design
- Analysis
- Manuscript preparation
Citation:
- Breast 2017, 31: 219
Scientific Finding:
Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework.
Services Used:
- Model development
- Confirmation
Citation:
- Genet. Med. 2018. Epub
Scientific Finding:
Describing the Spectrum of Patient Reported Outcomes after Radical Prostatectomy: Providing Information to Improve Patient Counseling and Shared Decision Making
Services Used:
- Nonparametric Bayesian mixed model for distribution of functional outcomes post-prostatectomy
Citation:
- Journal of Urology. 2018. Epub.
Scientific Finding:
Treatment of metastatic renal cell carcinoma in older patients: A network meta-analysis
Services Used:
- Joint network meta-analysis of mRCC therapies for older patients
Citation:
- Journal of Geriatric Oncology. 2018. Epub.
Scientific Finding:
Optimal First-Line Treatment of Metastatic Renal-Cell Carcinoma: A Network Meta-Analysis
Services Used:
- Joint network meta-analysis of first-line mRCC therapies
Citation:
- Kidney Cancer. 2018. 2(2):115-121.
Contact Us
Cancer Biostatistics Director
Y. Ann Chen, PhD
ann.chen@hci.utah.edu
Cancer Biostatistics Co-Director
Kenneth M. Boucher, PhD
ken.boucher@hci.utah.edu
Related Links
Governance
HCI Senior Director Oversight
Tracy Onega, PhD, MS
Faculty Advisory Committee Chair
Doug Sborov, MD, MS
Faculty Advisory Committee Vice Chair
Anne Kirchhoff, PhD, MPH
Faculty Advisory Committee Members
Ann Chen, PhD
Ken Boucher, PhD
David Lum, PhD
Benjamin Maughan, MD
Benjamin Spike, PhD
Katherine Varley, PhD